DACH1 a key protein for tumor suppression in ER+ breast cancer

	Tweet

Researchers from the Kimmel Cancer Center at Jefferson have identified a protein relationship that may be an ideal treatment target for ER+ breast cancer. The study was reported in the July 15 issue of Cancer Research.

DACH1, a cell fate determination factor protein, prevents cancer cell proliferation by repressing the function of estrogen receptorsin breast cancer, the researchers found. However, they also found that as the presence of DACH1 decreases in breast cancer, the presence of estrogen receptors increases, and vice versa.

Approximately 70% of breast cancers are ER+. Treatment for ER+ breast cancer usually consists of hormone therapy, which includes lowering the natural estrogen levels in the body or using synthetic drugs like tamoxifen, which compete with natural estrogen. However, this treatment only works for a few years.

"Eventually, cancer cells will circumvent the estrogen-dependent growth and find a different pathway through which they will proliferate,” said Vladimir Popov, a doctoral student in Biochemistry and Molecular Biology at Jefferson College of Graduate Studies of Thomas Jefferson University and the study’s first author. “Our lab has shown that there is a correlation between DACH1 and estrogen receptors. DACH1 is a naturally occurring repressor of estrogen receptor function in normal breast tissue, which makes it a promising therapeutic target for patients with ER+ breast cancer.”

DACH1 is expressed in normal breast tissue. As breast cancer develops and becomes more invasive, the expression of DACH1 decreases. In a previous study of more than 2,000 breast cancer patients, Jefferson researchers found that a lack of DACH1 expression was associated with a poor prognosis. Patients who did express DACH1 lived an average of 40 months longer.

“Many more studies need to be done, but there is strong evidence that DACH1 is a promising marker of survival and therapeutic target in patients with breast cancer,” said the study’s senior researcher Richard Pestell, M.D., Ph.D, who is director of the Kimmel Cancer Center and chair of the Cancer Biology department at Jefferson.

###

Contact: Emily Shafer

215-955-6300
Thomas Jefferson University

RELATED STORIES:
Scientists find new drug target in breast cancer   Information about the use and accuracy of breast cancer tests is lacking, study finds   Mammograms May Detect Some Cancers That Would Have Regressed   Gene acts as a brake on breast cancer progression   Overeating plus inactivity ups breast cancer risk   Virus kills breast cancer cells in laboratory   U-M researchers find genetic rearrangements driving 5 to 7 percent of breast cancers   Fertility issues in young women with breast cancer must be addressed   Diet may lower breast cancer risk before menopause   Painful hip fractures strike breast cancer survivors   Biomarker May Be an Early Predictor of Advanced Breast Cancer   UT Southwestern launches clinical trial for treatment of breast cancer using CyberKnife   Radiation After Mastectomy Improves Breast Cancer Survival   European ancestry increases breast cancer risk among Latinas   Early Xeloda does not help in breast cancer- study   Different Gene-Expression Predictors of Breast Cancer Agree   Ethnic breast cancer gap tied to mammography rates   Tamoxifen resistance—and how to defeat it   Gene Helps Protect Tumor Suppressor in Breast Cancer   Current Status of Prognostic Profiling in Breast Cancer: study   Research aims to starve breast cancer cells   Tracking and feedback registry may reduce racial disparities in breast cancer care

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]